Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 5/20 | 0.39 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9947171 | 0.84 | HTR2C (0.47) | HTR2CHTR2AHTR2BSLC9A1CHRM2 | |
| SCHEMBL9945850 | 0.82 | HTR2C (0.46) | HTR2CHTR2AHTR2BDPP4KDM1A | |
| SCHEMBL9947168 | 0.82 | HTR2C (0.45) | HTR2CHTR2AHTR2BSLC9A1CHRM2 | |
| SCHEMBL9947172 | 0.79 | HTR2C (0.44) | HTR2CHTR2AHTR2BSLC9A1CHRM2 | |
| SCHEMBL15763556 | 0.78 | HTR2C (0.41) | HTR2CHTR2AHTR2BSLC9A1CHRM2 | |
| Hydrochloric Acid SCHEMBL8467719 | 0.78 | HTR2C (0.46) | HTR2CHTR2AHTR2BSLC9A1CHRM2 | |
| SCHEMBL7865958 | 0.75 | HTR2C (0.66) | HTR2CHTR2AHTR2BSLC9A1DPP4 | |
| SCHEMBL7096910 | 0.75 | HTR2C (0.66) | HTR2CHTR2AHTR2BSLC9A1DPP4 | |
| SCHEMBL7096911 | 0.75 | HTR2C (0.66) | HTR2CHTR2AHTR2BSLC9A1DPP4 | |
| Hydrochloric Acid SCHEMBL8156348 | 0.74 | HTR2C (0.67) | HTR2CHTR2AHTR2BSLC9A1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422229-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140155490-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20100305212-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | HTR2C 1/4885HTR2A 7/4885HTR2B 21/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | HTR2C 1/4885HTR2A 7/4885HTR2B 21/4885 |
| US-20140155490-A1 | THERAPEUTIC COMPOUNDS | HTR2C, HTR3B, HTR2A | HTR2C 1/4885HTR2A 3/4885HTR2B 10/4885 |
| US-20100305212-A1 | THERAPEUTIC COMPOUNDS | HTR2C, HTR3B, HTR2A | HTR2C 1/4885HTR2A 3/4885HTR2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.